Basilea Pharmaceutica AG Share Price Xetra
Equities
PK5
CH0011432447
Biotechnology & Medical Research
Sales 2024 * | 18Cr 20Cr 19Cr 1.68TCr | Sales 2025 * | 20Cr 22Cr 20Cr 1.83TCr | Capitalization | 47Cr 52Cr 49Cr 4.35TCr |
---|---|---|---|---|---|
Net income 2024 * | 2.6Cr 2.88Cr 2.68Cr 239.95Cr | Net income 2025 * | 2.9Cr 3.21Cr 2.99Cr 267.63Cr | EV / Sales 2024 * | 2.9 x |
Net Debt 2024 * | 5.68Cr 6.28Cr 5.85Cr 523.84Cr | Net Debt 2025 * | 1.25Cr 1.38Cr 1.29Cr 115.43Cr | EV / Sales 2025 * | 2.45 x |
P/E ratio 2024 * |
18.4
x | P/E ratio 2025 * |
16.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.61% |
Latest transcript on Basilea Pharmaceutica AG
Managers | Title | Age | Since |
---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 59 | 01/14/01 |
Adesh Kaul
DFI | Director of Finance/CFO | 50 | 01/09/01 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 60 | 01/18/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nicole Onetto
BRD | Director/Board Member | 71 | 27/17/27 |
Leonard Kruimer
BRD | Director/Board Member | 66 | 01/22/01 |
Director/Board Member | 69 | 09/13/09 |
1st Jan change | Capi. | |
---|---|---|
+16.60% | 4.55TCr | |
-9.63% | 3.85TCr | |
+38.08% | 3.81TCr | |
+28.04% | 3.07TCr | |
-8.64% | 2.6TCr | |
+11.86% | 2.59TCr | |
+45.08% | 1.41TCr | |
+33.68% | 1.27TCr | |
-7.83% | 1.13TCr |